ARDX ARDELYX, INC.
FY2025 10-K
ARDELYX, INC. (ARDX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 19, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development and commercialization of innovative medicines focused on tenapanor-based therapies for gastrointestinal and kidney diseases
- • New emphasis on Phase 3 trial initiation in January 2026 for tenapanor in chronic idiopathic constipation (CIC), targeting a new patient population of 34 million Americans
Management Discussion & Analysis
- • Total revenue $407.3M, up 22% YoY from $333.6M in 2024; product sales $377.8M, up 18% YoY from $319.2M
- • Operating expenses $448.3M, up 24% YoY from $361.6M; cost of sales down 22% to $39.5M vs $50.6M; R&D up 37% to $71.5M; SG&A up 30% to $337.2M
Risk Factors
- • Regulatory risk: CMS inclusion of XPHOZAH in ESRD PPS on Jan 1, 2025, eliminated Medicare Part D coverage, materially reducing 2025 XPHOZAH revenue
- • Geopolitical/macro risk: Foreign price controls in Europe, Canada, Japan, China may limit IBSRELA and XPHOZAH pricing and reduce international revenue
Get deeper insights on ARDELYX, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.